Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

DNAnexus Announces Collaboration with AlidaBio to Enhance RNA Modification and Expression Analysis

AlidaBio EpiPlex™ customers now have cloud access to the EpiScout™ analysis software on DNAnexus’ secure, scalable precision health data cloud platform

DNAnexus, Inc., provider of the leading enterprise platform for precision health data, and Alida Biosciences (AlidaBio), a leader in RNA epigenomic research tools, today announced a strategic collaboration designed to accelerate discovery and advance research into epitranscriptomics activity, the complex chemical modifications to RNA that regulate gene expression.

Epitranscriptomics research has the potential to significantly affect patient lives. Gaining an understanding of RNA epigenetic modifications offers opportunities for identifying new biomarkers and drug targets that are associated with diseases such as cancer and neurological disorders. These markers can indicate how patients will respond to certain treatments and help ensure they are enrolled in the right clinical trials that match them to the treatments most likely to give positive outcomes. The DNAnexus collaboration with Alida Biosciences allows researchers to establish these markers, enabling more personalized medicine approaches.

As part of the collaboration, AlidaBio’s EpiScout™ Analysis Suite Application will be exclusively hosted on the DNAnexus cloud platform. The user-friendly informatics solution was designed to accurately detect, analyze, and visualize epitranscriptomics activity. The EpiScout software analyzes data from sequencing libraries produced with AlidaBio’s EpiPlex™ RNA modification encoding kits. It includes custom algorithms for data normalization and uses machine learning-based peak calling technology to accurately identify regions of significant read enrichment and quantify the peaks. With seamless interpretation and data sharing, researchers can focus on biological discovery and large-scale experiments rather than technological challenges and workflow limitations.

“AlidaBio is proud to be part of the DNAnexus ecosystem for precision health data,” said Gudrun Stengel, PhD, CEO of AlidaBio. “The EpiScout application is an intuitive, cost-effective solution designed to accelerate the data-to-answer workflow for labs without specialized epitranscriptomics bioinformatics expertise.”

“While NGS data is common today, complex analyses often require specific bioinformatics expertise. A cloud-based analysis tool like the DNAnexus platform empowers scientists at any level to analyze data while ensuring reproducibility,” said Hoang Quoc Hai Pham, graduate student, City of Hope National Medical Center. “It also makes data more accessible and easily shareable with collaborators. I enjoyed using it for my [EpiPlex] m6A-seq samples.”

Today, DNAnexus has more than 45,000 registered users across 48 countries and actively manages more than 105 petabytes of complex clinical, genomic, proteomic, and other multiomic datasets on behalf of a growing network of collaborators. Its comprehensive enterprise platform for precision health data meets the most rigorous industry standards for data quality, security, privacy, and regulatory compliance.

“This collaboration with AlidaBio is a great example of how we continue to expand our cloud-based applications and enable our customers to unlock more actionable information hidden in their large multiomic datasets,” said Thomas Laur, CEO of DNAnexus. “Together, we are making these easy-to-use epitranscriptomics tools accessible, empowering more researchers worldwide to discover the next wave of biomarkers and therapeutics.”

About Alida Biosciences

Alida Biosciences is revolutionizing epigenomics and leading the way in next-generation RNA modification analysis, empowering breakthroughs in research, therapeutics, and diagnostics. Founded in 2020, AlidaBio develops groundbreaking products that simplify bioinformatics, enabling concurrent analysis of multiple RNA modifications with relative quantification. Its solutions utilize RNA inputs suitable for clinically relevant samples, offering unparalleled workflow efficiency and accessibility. AlidaBio is proudly backed by Genoa Ventures, FusionX Ventures, and Vertical Venture Partners, alongside ongoing support from multiple SBIR grants from the National Human Genome Research Institute. For more information, please visit www.alidabio.com.

About DNAnexus

DNAnexus, the enterprise platform for precision health data, is on a mission to accelerate the development, approval, and delivery of personalized treatments. Building on more than 15 years of bioinformatics innovation and genomics expertise, DNAnexus powers a connected data ecosystem trusted by the world’s precision health leaders. This flexible ecosystem makes omics and real-world data accessible, actionable, and secure while unlocking insights that improve patient lives. For more information, visit www.dnanexus.com or follow @DNAnexus on social media.

“This collaboration with AlidaBio is a great example of how we continue to expand our cloud-based applications and enable our customers to unlock more actionable information hidden in their large multiomic datasets,” said Thomas Laur, CEO of DNAnexus.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.